Publication Date
| In 2025 | 0 |
| Since 2024 | 1 |
| Since 2021 (last 5 years) | 1 |
| Since 2016 (last 10 years) | 2 |
| Since 2006 (last 20 years) | 2 |
Descriptor
| Drug Therapy | 2 |
| Randomized Controlled Trials | 2 |
| Adults | 1 |
| Affordances | 1 |
| Asperger Syndrome | 1 |
| Attitudes | 1 |
| Autism | 1 |
| Autism Spectrum Disorders | 1 |
| Barriers | 1 |
| Children | 1 |
| Experience | 1 |
| More ▼ | |
Source
| Autism: The International… | 2 |
Author
| Alba Realpe | 1 |
| Ali, Sanjida | 1 |
| Aman, Michael G. | 1 |
| Andersen, Kristen A. | 1 |
| Dheeraj Rai | 1 |
| Graham, Stephen M. | 1 |
| Hardan, Antonio Y. | 1 |
| Hendren, Robert L. | 1 |
| Jia, X Daniel | 1 |
| Lateiner, Jordan E. | 1 |
| Lorcan Kenny | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
| United Kingdom | 1 |
Laws, Policies, & Programs
Assessments and Surveys
| Social Responsiveness Scale | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkLucy Beasant; Alba Realpe; Sarah Douglas; Lorcan Kenny; Dheeraj Rai; Nicola Mills – Autism: The International Journal of Research and Practice, 2024
The purpose of this study is to explore the views of autistic adults on randomised controlled trials, specifically on processes such as randomisation and blinding, to understand the barriers and facilitators for recruiting autistic people to randomised controlled trials involving medications. We conducted one-to-one interviews with 49 autistic…
Descriptors: Autism Spectrum Disorders, Adults, Attitudes, Randomized Controlled Trials
Hardan, Antonio Y.; Hendren, Robert L.; Aman, Michael G.; Robb, Adelaide; Melmed, Raun D.; Andersen, Kristen A.; Luchini, Rachel; Rahman, Rezwanur; Ali, Sanjida; Jia, X Daniel; Mallick, Madhuja; Lateiner, Jordan E.; Palmer, Robert H.; Graham, Stephen M. – Autism: The International Journal of Research and Practice, 2019
Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind,…
Descriptors: Children, Autism, Pervasive Developmental Disorders, Drug Therapy
